Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GPR39 | O43194 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799489 | 0.85 | NOS1 (0.47) | NOS1NOS3CCNT1ALDH1A1HPGD | |
| SCHEMBL8275651 | 0.85 | NOS1 (0.42) | NOS1NOS3ALDH1A1HPGDADORA3 | |
| SCHEMBL5799995 | 0.84 | NOS1 (0.47) | NOS1NOS3CCNT1ALDH1A1HPGD | |
| SCHEMBL5800402 | 0.83 | NOS1 (0.65) | NOS1NOS3CCNT1GPR39 | |
| SCHEMBL5796485 | 0.80 | NOS1 (0.42) | NOS1NOS3CCNT1ALDH1A1HPGD | |
| SCHEMBL6715081 | 0.76 | NOS1 (0.44) | NOS1NOS3ALDH1A1ADORA3ADORA1 | |
| SCHEMBL7039704 | 0.74 | NOS1 (0.38) | NOS1NOS3CCNT1 | |
| SCHEMBL8353981 | 0.73 | NOS1 (0.46) | NOS1NOS3CCNT1ALDH1A1HPGD | |
| SCHEMBL5773325 | 0.71 | HTR2A (0.39) | — | |
| SCHEMBL8275649 | 0.69 | NOS1 (0.47) | NOS1NOS3ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434624-B1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | disclosed |
| EP-1434624-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2251/4885NOS3 1089/4885CCNT1 4379/4885 |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | NOS3, NOS1, NOS2 | NOS1 2/4885NOS3 1/4885CCNT1 1911/4885 |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PNMT, HTR6, HTR2C | NOS1 2336/4885NOS3 1069/4885CCNT1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.